文献速递角膜与眼表疾病

强脉冲光治疗睑板腺功能障碍的阶梯延长方案与按需方案的比较

"Stepwise Extension Treatment Protocol" versus "Pro Re Nata Regimen" of Intense Pulsed Light for Meibomian Gland Dysfunction.
PubMed 文献 · Ophthalmology · 2025-10-10

这项前瞻性对照研究纳入睑板腺挤出性或睑脂质量分级≥2的参与者,比较强脉冲光阶梯延长治疗(SET)方案与按需(PRN)方案联合热敷的疗效。24个月时两组在眼表疾病指数(OSDI)、睑板腺挤出性(MGE)、睑脂质量(MQ)上的改善均无显著差异,但SET组强脉冲光次数更多;MGE 3级患者中SET组改善更明显。

要点

  • 两组24个月OSDI、MGE、MQ较基线的改善均无显著差异(均P>0.05)。
  • 24个月强脉冲光平均次数SET组14.8±4.2次(中位13.0)vs PRN组10.0±6.4次(中位8.0),P<0.01。
  • MGE 3级患者中SET组改善优于PRN组(P<0.01),PRN组出现发作性加重。

核心结论

  • SET与PRN方案均可改善睑板腺功能障碍的症状与功能,轻中度患者对两种方案反应均良好。
  • 作者认为,重度睑板腺功能障碍中SET方案可能提供更稳定的长期控制,提示个体化治疗的重要性。

研究设计与样本

  • 前瞻性对照研究,纳入睑板腺挤出性或睑脂质量分级≥2的参与者412例,308例(74.8%)完成研究。
  • 所有参与者初始接受4次强脉冲光治疗,间隔4周;SET组根据临床反应将间隔延长或缩短2周,PRN组仅在符合预设标准时复治。
  • 预设复治标准为OSDI≥23或较前次就诊升高,同时伴MGE或MQ≥2;采用线性混合效应模型(LMM)分析。

主要发现

  • 基线至24个月OSDI、MGE、MQ平均变化:SET组为-16.0、-0.8、-0.9,PRN组为-15.3、-0.7、-0.8(均P>0.05)。
  • 基线MGE或MQ分级≤2的患者中,两种方案均使评分有效降至1.5以下。
  • MGE 3级患者中SET组改善更明显(P<0.01),PRN组出现发作性加重。
  • 24个月强脉冲光平均次数SET组14.8±4.2次(中位13.0)vs PRN组10.0±6.4次(中位8.0),P<0.01。

关键数值与推荐

  • 复治指征:OSDI≥23或较前次就诊升高,同时MGE或MQ≥2。
  • 初始4次强脉冲光间隔4周;SET组按临床反应将间隔延长或缩短2周。
  • 主要结局为OSDI、MGE、MQ的纵向变化;次要结局为基线至24个月强脉冲光总次数。

临床怎么用

  • 作者认为,轻中度睑板腺功能障碍患者对SET或PRN方案反应均良好。
  • 作者认为,重度睑板腺功能障碍中SET方案可能提供更稳定的长期控制,提示个体化治疗的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy of a stepwise extension treatment (SET) protocol and a pro re nata (PRN) regimen of intense pulsed light (IPL) therapy with warm compresses for meibomian gland dysfunction (MGD). DESIGN: A prospective, comparative study. PARTICIPANTS: Participants with meibomian gland expressibility (MGE) or meibum quality (MQ) grade 2 or higher. METHODS: All participants initially received 4 IPL sessions at 4-week intervals. In the SET group, intervals were extended or shortened by 2 weeks based on clinical response. In the PRN group, re-treatment was performed only when predefined criteria were met. Re-treatment was indicated if the Ocular Surface Disease Index (OSDI) was ≥23 or increased from the prior visit, along with MGE or MQ ≥2. A linear mixed-effects model (LMM) was used for analysis. MAIN OUTCOME MEASURES: The primary outcome measures were the longitudinal changes in the Ocular Surface Disease Index (OSDI), meibomian gland expressibility (MGE), and meibum quality (MQ). The total number of IPL sessions administered from baseline to 24 months was assessed as a secondary outcome. RESULTS: Among 412 participants, 308 (74.8 %) completed the study. Mean changes in OSDI, MGE, and MQ from baseline to 24 months were -16.0, -0.8, and -0.9 in the SET group and -15.3, -0.7, and -0.8 in the PRN group, respectively (all P > 0.05). In patients with baseline MGE or MQ grade ≤2, both protocols effectively reduced scores to below 1.5. In patients with MGE grade 3, the SET group demonstrated greater improvement (P < 0.01), and episodic exacerbations were observed in the PRN group. The mean number of IPL sessions over 24 months was 14.8 ± 4.2 (median 13.0) in the SET group and 10.0 ± 6.4 (median 8.0) in the PRN group (P < 0.01). CONCLUSIONS: Both SET and PRN regimens led to symptomatic and functional improvement in MGD. Patients with mild-to-moderate MGD responded well to either regimen. In severe MGD, the SET protocol may provide more stable long-term control, suggesting the importance of individualized treatment approaches. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Ahn H, Chung JL, Jun I, et al. "Stepwise Extension Treatment Protocol" versus "Pro Re Nata Regimen" of Intense Pulsed Light for Meibomian Gland Dysfunction. Ophthalmology. 2025. PMID: 41076032. doi:10.1016/j.ophtha.2025.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。